Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Ghulam Idrees

Internal Medicine Marion, OH Medical Doctor

NPI 1447218292 CMS profile 292523

1025 Harding Memorial Pkwy, Marion, OH 43302

Open in the dashboard

General payments

$9,135

645 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Ghulam Idrees of Marion, OH is reported in the CMS Open Payments database as having received $9,135 across 645 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 94th percentile of Internal Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $821 44
2024 General $1,344 80
2023 General $991 63
2022 General $1,304 96
2021 General $1,405 89
2020 General $1,466 113
2019 General $1,804 160

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Ghulam Idrees
  • Internal Medicine median
  • Middle half of Internal Medicine
  • National median

In program year 2025, general payments to Ghulam Idrees were reported at $821. Among 52,115 Internal Medicine profiles paid that year, the median was $156 and the middle half received between $47 and $551.

Show as a table
Year Ghulam Idrees Internal Medicine median Middle half National median
2019 $1,804 $159 $48–$570 $163
2020 $1,466 $119 $33–$402 $114
2021 $1,405 $135 $37–$521 $132
2022 $1,304 $141 $42–$496 $149
2023 $991 $149 $45–$519 $160
2024 $1,344 $154 $47–$537 $164
2025 $821 $156 $47–$551 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AstraZeneca Pharmaceuticals LP $1,178 50 payments
  2. AbbVie, Inc. $1,010 72 payments
  3. Novo Nordisk Inc $922 98 payments
  4. Pfizer Inc. $890 84 payments
  5. Novartis Pharmaceuticals Corporation $611 37 payments
  6. Lilly USA, LLC $473 38 payments
  7. GlaxoSmithKline, LLC. $457 46 payments
  8. Bayer HealthCare Pharmaceuticals Inc. $445 31 payments
  9. Astellas Pharma US Inc $352 14 payments
  10. Boehringer Ingelheim Pharmaceuticals, Inc. $308 21 payments
  11. Other $2,489 154 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $8,863 641 payments
  2. Education $183 3 payments
  3. Debt forgiveness $88 1 payment
Products named General payments · program years 2019–2025
  1. FARXIGA $767 28 payments
  2. ELIQUIS $475 43 payments
  3. Kerendia $445 31 payments
  4. UBRELVY $433 30 payments
  5. Ozempic $427 49 payments
  6. ENTRESTO $367 24 payments
  7. RYBELSUS $343 37 payments
  8. SYMBICORT $281 8 payments
  9. TRELEGY ELLIPTA $274 21 payments
  10. VRAYLAR $273 24 payments
  11. Other $7,376 545 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 222 drugs

Part D claims

19,679

Median for Internal Medicine: 777

Drug cost

$1,288,610

Median for Internal Medicine: $73,373

Branded share of claims

22.7%

Median for Internal Medicine: 19.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 509 $194,522
Januvia Sitagliptin Phosphate Brand 268 $82,399
Tradjenta Linagliptin Brand 236 $73,584
Ozempic Semaglutide Brand 63 $73,163
Farxiga Dapagliflozin Propanediol Brand 160 $56,574
Linzess Linaclotide Brand 89 $50,177
Jardiance Empagliflozin Brand 138 $48,368
Nuplazid Pimavanserin Tartrate Brand 18 $46,077
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 55 $40,814
Xarelto Rivaroxaban Brand 111 $39,083

The 10 drugs with the highest cost, of 222 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 47 billing codes

Paid by Medicare

$156,658

Of which drugs: $3,317

Medicare patients

618

Average age 77

Services billed

2,688

351 women, 267 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 65%
Depression 48%
Diabetes 44%
Chronic kidney disease 43%
Ischemic heart disease 42%
Heart failure 40%
Atrial fibrillation 36%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Vaccine for influenza for injection into muscle 90653 Office 25 25 $2,046

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 35 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
TRELEGY ELLIPTA
$106 55 —
Kerendia
$102 29 —
FARXIGA
$97 160 —
LEQVIO
$77 — —
SPRAVATO
$74 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 35 with Patron

Records

645 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Internal Medicine in Ohio

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record